Evidence map›Paper›PMID 31882800›Full record

ArticleScientific reports2019

Recombinant HIV-1 vaccine candidates based on replication-defective flavivirus vector.

M Giel-Moloney, M Esteban, B H Oakes, M Vaine, B Asbach, R Wagner, G J Mize, A G Spies, J McElrath, M Perreau and 24 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 11 institutions in 5 countries.

M Giel-MoloneySanofi Pasteur, Cambridge, MA, 02139, USA. Maryann.Giel-Moloney@sanofi.com.
M EstebanCentro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
B H OakesSanofi Pasteur, Cambridge, MA, 02139, USA.
M VaineSanofi Pasteur, Cambridge, MA, 02139, USA.
B AsbachUniversity of Regensburg (UREG), Institute of Medical Microbiology and Hygiene, 93053, Regensburg, Germany.
R WagnerUniversity of Regensburg (UREG), Institute of Medical Microbiology and Hygiene, 93053, Regensburg, Germany.
G J MizeFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98109, USA.
A G SpiesFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98109, USA.
J McElrathFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98109, USA.
M PerreauService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, 1011, Lausanne, Switzerland.
T RogerInfectious Diseases Service, Department of Medicine, Lausanne University Hospital, 1011, Lausanne, Switzerland.
A IvesInfectious Diseases Service, Department of Medicine, Lausanne University Hospital, 1011, Lausanne, Switzerland.
T CalandraInfectious Diseases Service, Department of Medicine, Lausanne University Hospital, 1011, Lausanne, Switzerland.
D WeissBioqual Inc, Rockville, Maryland, 20850, USA.
B PerdigueroCentro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
K V KiblerArizona State University (ASU), Tucson, AZ, 85745, USA.
B JacobsArizona State University (ASU), Tucson, AZ, 85745, USA.
S DingEuroVacc, Amsterdam, The Netherlands.
G D TomarasDuke University Medical Center, Durham, North Carolina, 27710, USA.
D C MontefioriDuke University Medical Center, Durham, North Carolina, 27710, USA.
G FerrariDuke University Medical Center, Durham, North Carolina, 27710, USA.
N L YatesDuke University Medical Center, Durham, North Carolina, 27710, USA.
M RoedererVaccine Research Center, NIAID, NIH, Bethesda, MD, 20892, USA.
S F KaoVaccine Research Center, NIAID, NIH, Bethesda, MD, 20892, USA.
K E FouldsVaccine Research Center, NIAID, NIH, Bethesda, MD, 20892, USA.
B T MayerFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98109, USA.ORCID http://orcid.org/0000-0003-2258-5276
C BennettFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98109, USA.
R GottardoFred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, 98109, USA.ORCID http://orcid.org/0000-0002-3867-0232
M ParringtonSanofi Pasteur, Cambridge, MA, 02139, USA.
J TartagliaSanofi Pasteur, Cambridge, MA, 02139, USA.
S PhogatSanofi Pasteur, Cambridge, MA, 02139, USA.
G PantaleoService of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, 1011, Lausanne, Switzerland.
H KleanthousSanofi Pasteur, Cambridge, MA, 02139, USA.
K V PugachevSanofi Pasteur, Cambridge, MA, 02139, USA.
Sanofi (United States) · USFred Hutch Cancer Center · USUniversity of Lausanne · CHDuke Medical Center · USNational Institutes of Health · USArizona State University · USCentro Nacional de Biotecnología · ESBioqual · USInstitute of Medical Microbiology and Hygiene · DESanofi (France) · FRUniversity Hospital Regensburg · DE

Funding

Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
NIAID NIH HHS P30 AI064518
6 · The paper itself

Abstract

Multiple approaches utilizing viral and DNA vectors have shown promise in the development of an effective vaccine against HIV. In this study, an alternative replication-defective flavivirus vector, RepliVax (RV), was evaluated for the delivery of HIV-1 immunogens. Recombinant RV-HIV viruses were engineered to stably express clade C virus Gag and Env (gp120TM) proteins and propagated in Vero helper cells. RV-based vectors enabled efficient expression and correct maturation of Gag and gp120TM proteins, were apathogenic in a sensitive suckling mouse neurovirulence test, and were similar in immunogenicity to recombinant poxvirus NYVAC-HIV vectors in homologous or heterologous prime-boost combinations in mice. In a pilot NHP study, immunogenicity of RV-HIV viruses used as a prime or boost for DNA or NYVAC candidates was compared to a DNA prime/NYVAC boost benchmark scheme when administered together with adjuvanted gp120 protein. Similar neutralizing antibody titers, binding IgG titers measured against a broad panel of Env and Gag antigens, and ADCC responses were observed in the groups throughout the course of the study, and T cell responses were elicited. The entire data demonstrate that RV vectors have the potential as novel HIV-1 vaccine components for use in combination with other promising candidates to develop new effective vaccination strategies.

Indexed as

Genetic VectorsAIDS VaccinesAnimalsAntibodies, NeutralizingChlorocebus aethiopsCross ReactionsDefective VirusesFemaleFlavivirusHIV-1HIV InfectionsMacaca mulattaMiceMice, Inbred BALB CVaccines, SyntheticVero CellsAIDS VaccinesAntibodies, NeutralizingVaccines, Synthetic

Identifiers

PMID31882800
PMCPMC6934588
OpenAlexW2998139942

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.